Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC w...

Full description

Saved in:
Bibliographic Details
Published in:JTO clinical and research reports 2021-08, Vol.2 (8), p.100202, Article 100202
Main Authors: Su, Po-Lan, Lin, Chien-Yu, Chen, Yi-Lin, Chen, Wan-Li, Lin, Chien-Chung, Su, Wu-Chou
Format: Article
Language:English
Subjects:
Adenocarcinoma
BRAF K601E mutation
Case Report
Dabrafenib
Trametinib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC with a BRAF K601E mutation, a class II BRAF mutation, who had a durable response to targeted therapy with combined dabrafenib and trametinib.
ISSN:2666-3643
2666-3643
DOI:10.1016/j.jtocrr.2021.100202